LEADOPTIK is a California company making an optical imaging tool that shows doctors in real time whether a biopsy needle is in a small lung nodule. Its aim is earlier lung cancer diagnosis.
Leadoptik Inc., of San Jose, California, states its mission as improving patient lives through early lung cancer detection. Its flagship Last Inch Assessment (LIA) technology provides real-time microstructure imaging for pulmonary imaging and biopsy; a clinical adviser quoted on its website says the company is preparing for its FDA submission. In fiscal year 2026 NCI awarded it USD 1,477,882 under SBIR grant 1R44CA314574-01 (Optical Precision Targeting for Informed Cancer biopsy), whose abstract addresses the low diagnostic yield of radial endobronchial ultrasound for peripheral lung nodules under 20 mm.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR Phase II (R44) award 1R44CA314574-01: Optical Precision Targeting for Informed Cancer biopsy (OPTIC) | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Last Inch Assessment is an optical imaging tool from LEADOPTIK that lets doctors see, during a lung biopsy, whether the needle is inside a small nodule. It is in development and not yet cleared by the FDA.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/